Lidocain Accord (Lidocaine Hydrochloride)

Lidocaine hydrochloride blocks voltage‑gated sodium channels on neuronal membranes, stabilizing them in an inactive state. This prevents the rapid influx of sodium ions required for depolarisation, thereby halting the generation and propagation of nerve impulses and producing a reversible loss of sensation in the targeted area.

The appropriate dose of Lidocain Accord is determined by the prescribing clinician based on the specific procedure, route of administration, patient weight, and clinical condition. Dosage regimens are individualized and should follow local guidelines and the prescriber’s judgment.

Safety data for lidocaine hydrochloride in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Lidocain Accord, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lidocain Accord offers a rapid onset and moderate duration of action, making it suitable for short‑ to medium‑length procedures. Compared with longer‑acting agents such as bupivacaine, lidocaine provides quicker recovery of motor function but may require repeat dosing for prolonged analgesia. Its safety profile is well‑established for the indicated routes.

Lidocain Accord should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. The container should remain sealed until use, and any unused portion should be discarded according to local regulations.

Lidocain Accord is administered by a qualified healthcare professional via epidural, intramuscular or intravenous injection, depending on the clinical indication. The solution is injected directly into the target tissue or vascular compartment using aseptic technique and appropriate dosing equipment.

The most serious risks include cardiovascular toxicity such as arrhythmias or cardiac arrest, central nervous system toxicity leading to seizures or loss of consciousness, and severe allergic reactions including anaphylaxis. Immediate medical attention is required if any of these events occur.

Lidocain Accord should be avoided in patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics, in individuals with severe heart block or uncontrolled arrhythmias, and in patients where the risk of systemic toxicity cannot be adequately monitored.